We would like to thank Dr. Yao Yu and Dr. Yisen Zhang for their useful comments about our article. First, we did not conclude that the neutrophil-tolymphocyte ratio (NLR) is a suggestive clinical marker for diagnosing certain solid malignancies. The NLR has been reported as a useful systematic inflammatory response marker in malignancies.1,2 In addition, previous investigations have shown that NLR is a useful marker for predicting the prognosis of various malignant diseases, and a higher NLR has been associated with a poorer prognosis.3 Our study concluded that NLR is also influenced by cancer progression in renal transplant patients.4 Second, as Dr. Yao and colleagues mentioned, renal transplant patients in our study received a number of different drugs for controlling organ resection. We therefore showed for the first time the changes over time in NLR in nonmalignant patients receiving steroids and other immunosuppressive drugs postoperatively. We then compared the NLR between the nonmalignant and malignant groups.
In addition, our study had several limitations, including the number of patients and variations in the type of malignant disease. We therefore agree that further examinations concerning the NLR in renal transplant patients are needed. Despite these limitations, we introduced for the first time our hypothesis concerning NLR after renal transplant.
Volume : 17
Issue : 1
Pages : 129 - 129
DOI : 10.6002/ect.2018.0217R
From the Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
Acknowledgements: The authors have no sources of funding for this study and have no conflicts of interest to declare.
Corresponding author: Takashi Kawahara, Department of Urology and Renal Transplantation, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama City, Kanagawa, Japan
Phone: +81 45 261 5656